“Rohit Srivastava views the pharmaceutical sector as a pure defensive bet during difficult markets. He suggests pharma stocks can provide stability and act as a hedge, making them an area to consider amidst broader market volatility.”
Rohit Srivastava’s track record: 16 graded calls · 95% CI 39–82%
Nifty PharmaBullishCalled 11 Mar 2026Graded 19 Jul 2026
Nifty Pharma declined from ₹23275.20 to ₹22100.10 (-5.05%) over 30 days, contradicting the bullish defensive bet claim.
Read the original articleSee Rohit Srivastava’s full track record